Johnson & Johnson Receives Approval for TECNIS PureSee Intraocular Lens for Cataract Surgery
Friday, March 13, 2026
Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for the TECNIS PureSee intraocular lens (IOL), an extended depth of focus (EDOF) lens designed for use in cataract surgery.
Cataracts develop naturally as the eye ages and can make daily activities such as reading, driving and recognising faces more difficult. Cataract surgery involves removing the cloudy natural lens and replacing it with an artificial lens, helping restore vision. The TECNIS PureSee IOL is designed to address both cataract-related vision loss and presbyopia, a condition in which the eyes gradually lose the ability to focus on nearby objects.
The lens is expected to become available to patients in the United States later this year.
The newly approved lens provides a wider range of vision by offering extended depth of focus. It supports clear distance and intermediate vision and also provides some near-vision capability. Clinical findings indicate that a large proportion of patients experienced minimal visual disturbances following implantation.
The TECNIS PureSee IOL is also reported to maintain contrast sensitivity comparable to an aspheric monofocal IOL. Contrast sensitivity refers to the ability to distinguish objects from their background, which is particularly important in low-light or foggy conditions. Maintaining this visual quality can help patients achieve clearer and more reliable vision after surgery.
Built on the TECNIS lens platform, the device combines advanced optical design with proprietary materials. The lens is intended to reduce patients’ reliance on glasses after cataract surgery while supporting improved visual performance across different distances.
The approval further expands Johnson & Johnson’s surgical vision portfolio, which includes several intraocular lens technologies developed over the past 25 years. Each year, millions of patients worldwide receive TECNIS lenses during cataract procedures as part of efforts to improve visual outcomes.
Source: businesswire.com
